Me CEO Anne Wojcicki and New Mountain Capital propose $2.53/share buyout to take company private, valuing it at $74.7M after ...

Sanofi & Teva's IBD drug duvakitug shows promise in Phase 2b with €1B sales potential by 2032, faces competition from Roivant ...

Amgen to invest $200M in new Hyderabad tech center through 2025, focusing on AI for drug development. Site opened Monday with ...

With help from its $43 billion Seagen merger, Pfizer will contribute its antibody-drug conjugates to Summit Therapeutics' ...

So far, only 22% of life sciences organizations have adopted AI at scale, yet 86% of healthcare and life sciences leaders ...

Phase 1b US study planned for 2026, as company competes with NS Pharma and Avidity Biosciences in exon 44 space ...

FDA denies Invivyd's EUA expansion for Pemgarda in Covid treatment while BioCryst reports positive Orladeyo data. AN2 changes endpoint, OS Therapies seeks partners & Eyenovia restructures.

Pfizer CEO Albert Bourla supports Trump administration at PhRMA Forum, while CDC postpones vaccine advisory meeting. Atomwise names Steve Worland as CEO, and Biogen licenses Dravet drug.

Tang Capital's Concentra Biosciences offers to buy Acelyrin for $3/share, challenging planned Alumis merger. Concentra would ...

Celia Witten, deputy director of the FDA's Center for Biologics Evaluation and Research, has left the FDA, adding to a wave ...

As he was testing new antivirals to halt a future pandemic, John Chodera encountered an unlikely set of new problems that ...

Pfizer ends commercialization of Beqvez hemophilia B gene therapy. CEO Kim Phelan of Coalition for Hemophilia B expresses ...